A predominant challenge in these studies is the ubiquitous expression of EP2/EP4 in various immune cell subsets within the tumor microenvironment, posing a substantial challenge for the clinical application of targeted EP2/EP4 receptor inhibition due to the anticipated deleterious side effects on normal immune function. The gene discussed is PTGER4; the disease is neoplasm.